Perampanel
Overview
Perampanel is a non-competitive AMPA receptor antagonist used as an adjunctive therapy for the treatment of partial-onset seizures and generalized tonic-clonic seizures in patients with epilepsy. It works by reducing the excessive excitability of neurons in the brain, which is a hallmark of seizure activity.
API suppliers (7)
Suppliers of Perampanel evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 6 of 7 suppliers.
2 of 7 hold a GMP certificate on record in the EU or UK registers
- TAPI NL BVNetherlands1 active DMF
- Zydus Lifesciences LimitedIndia1 active DMF GMP on record
- Intas Pharmaceuticals Ltd.India1 active DMF GMP on record
- MSN Organics Private LimitedIndia1 active DMF
- CHEMO SMS ENTERPRISE SLSpain1 active DMF
- Shandong Loncom Pharmaceutical Co.,ltd.China1 active DMF
- STHREE CHEMICALS PRIVATE LTD1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (27 approved US products), the latest listed US patent on Perampanel expires 1 Jul 2026 and exclusivity 14 Jun 2026. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Perampanel? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.